Cumberland Pharmaceuticals (NASDAQ:CPIX) Shares Cross Above 200-Day Moving Average – Here’s Why

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIXGet Free Report)’s share price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.39 and traded as high as $2.43. Cumberland Pharmaceuticals shares last traded at $2.32, with a volume of 168,176 shares traded.

Analysts Set New Price Targets

Separately, StockNews.com started coverage on Cumberland Pharmaceuticals in a research note on Friday. They set a “hold” rating for the company.

Read Our Latest Analysis on CPIX

Cumberland Pharmaceuticals Stock Down 2.2 %

The company has a market capitalization of $31.88 million, a P/E ratio of -2.95 and a beta of 0.30. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.13 and a quick ratio of 0.99. The company has a 50 day moving average of $1.40 and a 200-day moving average of $1.40.

About Cumberland Pharmaceuticals

(Get Free Report)

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.

Recommended Stories

Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.